Joined in 2023 
82 
63 About this deal
v) Resulting corporation is the only acquiring corporation. Immediately after the potential F reorganization, no corporation other than the resulting corporation may hold property that was held by the transferor corporation immediately before the potential F reorganization, if such other corporation would, as a result, succeed to and take into account the items of the transferor corporation described in section 381(c). Guidelines on the benchmarking of diversity practices including diversity policies and gender pay gap Regulatory Technical Standards on risk mitigation techniques for OTC derivatives not cleared by a central counterparty (CCP)
On a more technical basis, the Government stated that, "[w]ith respect to Section 332, the holdings of Revenue Ruling 59-296 … continue to reflect the position of the Treasury Department and the IRS." Interestingly, Revenue Ruling 59-296 also contained a ruling that there was no reorganization involving the insolvent target corporation, but the Government limited its affirmative statement of support to Section 332. One could interpret this asymmetrical treatment as supporting the proposition that an insolvent target corporation may engage in a reorganization with its corporate shareholder. This was confirmed in the recent decision in Lagenda Erajuta Sdn Bhd ( Grounds of Judgment dated 20 February 2020). Regulatory Technical Standards on the implementation of group wide AML/CFT policies in third countries Implementing Technical Standards on supervisory reporting amendments with regards to COREP, asset encumbrance and G-SIIs Joint ESMA and EBA Guidelines on the assessment of the suitability of members of the management body (revised)Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J. 2005;26(3):511-522. This substance is registered under the REACH Regulation and is manufactured in and / or imported to the European Economic Area, at ≥ 1 to < 10 tonnes per annum. Guidelines for the implementation of the framework for consolidated financial reporting (FINREP) – Recast (2006)
Guidelines on preventing the abuse of funds and certain crypto-assets transfers for money laundering and terrorist financing purposes Substances may have impurities and additives that lead to different classifications. If at least one company has indicated that the substance classification is affected by impurities or additives, this will be indicated by an informative sentence. However, substance notifications in the InfoCard are aggregated independently of the impurities and additives.
The CVA provisions are in sections 395 to 402 of the CA 2016, along with the Seventh and Eighth Schedule of the CA 2016. The JM provisions are in sections 403 to 430 of the CA 2016, along with the Ninth Schedule of the CA 2016. In both the CVA and JM provisions, there is clear language to allow for an automatic moratorium to restrain legal proceedings. Callaway, E. & Mallapaty, S. Novavax offers first evidence that COVID vaccines protect people against variants. Nature 590, 17 (2021). VDJ, 5′-mRNA, and feature barcode libraries were prepared using the 10× Chromium System (10X Genomics, Pleasanton, CA) according to the manufacturer’s instructions. The C Chromium Next GEM Single Cell 5′ Kit v2 (10X Genomics, PN-1000263), Chromium Single Cell Human BCR Amplification Kit (10X Genomics, PN-1000253), and 5′ Feature Barcode Kit (10X Genomics, PN-1000256), Library Construction Kit (10X Genomics, PN-1000190), and Dual Index Kit TT Set A (10X Genomics, PN-1000215), Dual Index Kit TN Set A (10X Genomics, PN-1000250) were used. All libraries were quantified by using Qubit 3.0 (Thermo Fisher), Fragment Analyzer, and qPCR. Sequencing was performed on a Hiseq 2500 platform running Rapid SBS Kit V2 2x100bp kit (Illumina, FC-402–4021), with 10 cycles for the i7 index and i5 index. Average sequencing depth aimed for the mRNA library is 20,000 read pairs per cell, 5000 read pairs per cell for the VDJ libraries, and 5000 read pairs for feature barcode libraries. In vitro expression of monoclonal antibodies (mAbs) Regulatory Technical Standards on assessment methodologies for the use of AMAs for operational risk
Regulatory Technical Standards amending the bilateral margin requirements with regards to intragroup contracts However, there is a balancing of the rights of the applicant company and the creditors. The applicant company must provide, among others, evidence of support from the company’s creditors for the intended or proposed compromise or arrangement, a brief description of the intended compromise or arrangement, a list of every secured creditor and a list of all unsecured creditors not related to the company. The Court may also require: Discussion Paper on the impact on the volatility of own funds of the revised IAS 19 and the deduction of defined pension assets from own fundsBiotinylated proteins were then conjugated to Biolegend TotalSeq™ PE or APC streptavidin oligos at a 5:1 molar ratio of antigen protein to PE/APC streptavidin oligos. The amount of antigen was chosen based on a fixed amount of 0.6 µg PE or APC streptavidin oligos. The antigen protein and streptavidin oligos were mixed and incubated on ice for 30 min. After incubation, antigen-streptavidin oligos were diluted to a final volume of 10 µL. Antigen-streptavidin oligo diluent was then centrifuged at 14,000 × g at 2–8 °C for 10 min. Nine microliter liquid was carefully pipetted out avoiding the bottom of the tube and transferred to a new tube. Antigen-streptavidin oligos were then used immediately for cell staining. 1 × 10 9 antigen-streptavidin oligos were used in every 1 × 10 6 cells in 100 µL.
Great Deal 
New Comment